Stoke therapeutics stock.

Stoke Therapeutics (NASDAQ:STOK) Second Quarter 2023 ResultsKey Financial Results. Net loss: US$30.7m (loss widened by 24% from 2Q 2022). US$0.69 loss per share (further deteriorated from US$0.63 ...Stoke Cares. Stoke employees care about building community both internally and externally. Company-sponsored activities include company gatherings and celebrations, efforts to give back to local communities, and opportunities to share interests and explore new pursuits — all within a respectful, friendly and diverse culture. According to the issued ratings of 8 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $21.00 with a high price target of $35.00 and a low price target of $12.00.View the latest Stoke Therapeutics Inc. (STOK) stock price, news, historical charts, analyst ratings and financial information from WSJ. Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2a study (ADMIRAL) of STK ...

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy …

Stoke Cares. Stoke employees care about building community both internally and externally. Company-sponsored activities include company gatherings and celebrations, efforts to give back to local communities, and opportunities to share interests and explore new pursuits — all within a respectful, friendly and diverse culture.

Aug 7, 2023 · Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 11.9% so far this month. During the month of August, Stoke Therapeutics Inc’s stock price has reached a high of $6.58 and a low of $5.40. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $5.79. Year to date ... 10 Jan 2022 ... Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating ...Meet Our Founders. Stoke was co-founded in 2014 by Professor Adrian Krainer, Ph.D. and Isabel Aznarez, Ph.D. who aimed to use their groundbreaking science targeting pre-mRNA splicing to develop precision medicines that treat the underlying cause of genetic diseases.BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 6, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe ...

Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.

25 Aug 2022 ... Stoke Therapeutics Inc. today announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who ...26 Apr 2023 ... Stoke Therapeutics, Inc. received authorization to initiate a UK-based Phase 1/2 study of STK-002, a treatment of autosomal dominant optic ...Mar 27, 2023 · Stoke Therapeutics Inc’s ( STOK) price is currently down 10.24% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $7.22. Over the last year, Stoke Therapeutics Inc has hit prices as high as $24.97 and as low as $6.88. Year to date, Stoke Therapeutics Inc’s stock is ... Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates. November 7, 2023 – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat ...Stock analysis for Stoke Therapeutics Inc (STOK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

12 hours ago · BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 - 5, in Orlando, Florida. Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida.Nov 27, 2023 · Stoke Therapeutics Stock Performance. Shares of STOK remained flat at $4.02 during midday trading on Monday. The stock had a trading volume of 22,709 shares, compared to its average volume of 304,770. (RTTNews) - Stoke Therapeutics, Inc. (STOK) Tuesday reported positive safety and efficacy data from two Phase 1/2a studies of its drug candidate STK-001 for the treatment of Dravet syndrome.26 Apr 2023 ... Stoke Therapeutics, Inc. received authorization to initiate a UK-based Phase 1/2 study of STK-002, a treatment of autosomal dominant optic ...

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein …Find the latest Coeptis Therapeutics Holdings, Inc. (COEP) stock quote, history, news and other vital information to help you with your stock trading and investing.

11 Nov 2023 ... Since July 2023, shares of Stoke's common stock have declined in value from a trading price of over $10.00 per share to a current trading price ...Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG remains neutral on the stock and ...Complete Stoke Therapeutics Inc. stock information by Barron's. View real-time STOK stock price and news, along with industry-best analysis.Dec 1, 2023 · Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low. Find the latest Allogene Therapeutics, Inc. (ALLO) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock to Avoid: Stoke Therapeutics, Inc. STOK is an early-stage biopharmaceutical company that develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases. Its lead clinical candidates are STK-001 and STK-002.Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.Nov 27, 2023 · Stoke Therapeutics Stock Performance. Shares of STOK remained flat at $4.02 during midday trading on Monday. The stock had a trading volume of 22,709 shares, compared to its average volume of 304,770.

Find the latest AN2 Therapeutics, Inc. (ANTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest TransCode Therapeutics, Inc. (RNAZ) stock quote, history, news and other vital information to help you with your stock trading and investing.

BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 8, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2022 and provided business updates.PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and ...Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Tuesday, November, 7th. The company reported ($0.55) earnings per share (EPS) for …Find the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics Inc stock price live 3.88, this page displays NASDAQ STOK stock exchange data. View the STOK premarket stock price ahead of the market session or assess the after hours quote.Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest $6.14 on Friday, far from its 12-month high of $22.87.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2023 and provided business updates including those related to STK-001, the …Shares of Stoke Therapeutics ... The clinical-stage biotech company released positive early trial news regarding its lead therapy, but the stock hit a new 52-week low at $6.12 a share. Stoke's ...Find the latest Relay Therapeutics, Inc. (RLAY) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest …

Find the latest Sorrento Therapeutics, Inc. (SRNEQ) stock quote, history, news and other vital information to help you with your stock trading and investing.Aug 8, 2022 · Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? Stoke Therapeutics Stock Performance. Shares of STOK remained flat at $4.02 during midday trading on Monday. The stock had a trading volume of 22,709 shares, compared to its average volume of 304,770.Instagram:https://instagram. uncirculated steel penny valueamdocs inc.otcmkts rkunybroadcom dividend Stoke Therapeutics (STOK) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Stoke Therapeutics, with a price target of $25.00. The company’s shares closed last ...Find the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing. employee engagement software marketjackson financial stock Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000. best ev stocks to buy now Nov 17, 2023 · Stoke Therapeutics Inc (NASDAQ: STOK) has seen a decline in its stock price by -9.54 in relation to its previous close of 4.61. However, the company has experienced a -7.95% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-10 that Stoke Therapeutics (STOK) stock is down 40% after failing to meet ... Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.